XTL Biopharmaceuticals Ltd. (XTLB) Cash Flow Statement
Where XTLB’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$1.0M
- Capital expenditures
- $0
- Free cash flow
- −$1.0M
- Returned to shareholders
- —
- Change in cash
- −$295,000 cash at year-end $76,000
Drawn to scale: where the cash came from and how it was used. Hover for values.
XTLB operating cash flow, capex and free cash flow
XTLB cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$1.7M2016 | −$1.0M2025 | — | |
| Capital expenditures | $66,0002016 | $02025 | −100.0% | |
| Free cash flow | −$1.8M2016 | −$1.0M2025 | — | |
| Free cash flow margin | −7,817.4%2016 | −370.7%2024 | +7,446.7 pts | |
| Operating cash flow / net income | −0.272018 | −2.412021 | −2.14 | |
| Stock-based compensation | $182,0002016 | $346,0002025 | +7.4%/yr | |
| Share buybacks (net) | $02016 | $02017 | — | |
| Capex / revenue | 287.0%2016 | 12.0%2024 | −275.0 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
XTLB cash flow by activity
XTLB net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
XTLB cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$7.0M | −$1.0M | −$1.8M | −$1.3M | $435,000 | −$3.0M | −$1.3M | $3.0M | −$781,000 | −$2.5M |
| Depreciation & amortization | $0 | $199,000 | $1,000 | $1,000 | $1,000 | $1,000 | $842,000 | $1,000 | $1,000 | $3,000 |
| Stock-based compensation | $346,000 | $264,000 | $3,000 | $14,000 | $37,000 | $51,000 | $5,000 | $24,000 | $40,000 | $182,000 |
| Change in working capital | −$2,000 | $189,000 | $64,000 | −$19,000 | −$54,000 | $45,000 | −$50,000 | −$8,000 | $52,000 | −$220,000 |
| Other non-cash items | $5.6M | −$1.2M | $1.0M | $451,000 | −$1.5M | $2.0M | −$358,000 | −$3.8M | −$437,000 | $848,000 |
| Cash from operating activities | −$1.0M | −$1.6M | −$707,000 | −$901,000 | −$1.0M | −$850,000 | −$908,000 | −$816,000 | −$1.1M | −$1.7M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | −$54,000 | $0 | $0 | $0 | −$1,000 | −$2,000 | −$2,000 | −$2,000 | −$66,000 |
| Investments (net) | $777,000 | −$844,000 | $41,000 | $36,000 | $8,000 | $32,000 | $2.1M | $778,000 | −$2.5M | −$66,000 |
| Acquisitions & other investing | −$255,000 | $54,000 | $0 | $0 | $0 | $1,000 | $2,000 | $2,000 | $2,000 | $66,000 |
| Cash from investing activities | $522,000 | −$844,000 | $41,000 | $36,000 | $8,000 | $32,000 | $2.1M | $778,000 | −$2.5M | −$66,000 |
| Financing activities | ||||||||||
| Share repurchases & issuance (net) | — | — | — | — | — | — | — | — | $4.9M | $5.3M |
| Net borrowing (repayment) | $208,000 | −$13,000 | $0 | $0 | — | — | — | — | — | — |
| Shares issued | $0 | $1.5M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $0 | $0 | $0 | $0 | $385,000 | $385,000 | $385,000 | $385,000 | $0 | −$5.3M |
| Cash from financing activities | $208,000 | $1.4M | $0 | $0 | $385,000 | $385,000 | $385,000 | $385,000 | $4.9M | $0 |
| Summary | ||||||||||
| Net change in cash | −$295,000 | −$1.0M | −$693,000 | −$875,000 | −$662,000 | −$824,000 | $1.2M | −$34,000 | $1.3M | −$1.8M |
| Cash at end of period | $76,000 | $371,000 | $1.4M | $2.1M | $3.0M | $3.6M | $4.5M | $3.3M | $3.3M | $2.0M |
| Free cash flow | −$1.0M | −$1.7M | −$707,000 | −$901,000 | −$1.0M | −$851,000 | −$910,000 | −$816,000 | −$1.1M | −$1.8M |
| Free cash flow margin | — | −370.7% | — | — | −71.6% | −3,039.3% | −1,318.8% | −1,569.2% | −3,879.3% | −7,817.4% |
| Capex / revenue | — | 12.0% | — | — | 0.0% | 3.6% | 2.9% | 3.8% | 6.9% | 287.0% |
| Operating cash flow / net income | — | — | — | — | −2.41 | — | — | −0.27 | — | — |
| Dec '22 | Sep '22 | Jun '22 | |
|---|---|---|---|
| Operating activities | |||
| Net income | −$748,000 | −$821,000 | −$285,000 |
| Depreciation & amortization | $250 | $250 | $250 |
| Stock-based compensation | $14,000 | −$9,000 | — |
| Other non-cash items | −$1.3M | $820,750 | −$72,250 |
| Cash from operating activities | −$2.0M | −$9,000 | −$357,000 |
| Investing activities | |||
| Capital expenditures | $0 | $0 | $0 |
| Financing activities | |||
| Shares issued | $0 | $0 | $0 |
| Summary | |||
| Net change in cash | −$529,314 | −$298,050 | −$357,000 |
| Cash at end of period | $7.4M | $7.9M | −$357,000 |
| Free cash flow | −$2.0M | −$9,000 | −$357,000 |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
XTLB cash generation
In fiscal 2025 (ended December 31, 2025), XTL Biopharmaceuticals generated -$1.0 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$1.0 million. Cash and equivalents fell by $0.3 million over the year.
Related: XTLB income statement, XTLB balance sheet. See the XTLB stock overview for the latest quote and news.
XTLB cash flow FAQ
What is XTL Biopharmaceuticals's free cash flow?
XTL Biopharmaceuticals's free cash flow was -$1.0 million in fiscal 2025: -$1.0 million of operating cash flow minus $0 of capital expenditures It was -$1.7 million a year earlier..
How much cash does XTL Biopharmaceuticals generate from operations?
XTL Biopharmaceuticals generated -$1.0 million of cash from operating activities in fiscal 2025.